All In Biotech

Drug Trial Radar · NCT03948347

Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus

Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus: A Prospective, Multicenter, Randomized, Blank-controlled,Blinded End-point Study.

Last checked: Nov 19, 2026Latest source record: Feb 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 1,708 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,708

Planned (sponsor's estimate)

Start

Jun 25, 2019

Primary completion

Dec 2023

Study completion Jun 2024

Sponsor

Lead sponsor
First Affiliated Hospital of Jinan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 13, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and efficacy of glucagon-like peptide-1 (GLP-1) analogue liraglutide in the treatment of acute minor stroke (National Institute of Health stroke scale, NIHSS ≤ 3) or high-risk transient ischemic attack (TIA) (ABCD2 score ≥ 4 ) patients with type 2 diabetes mellitus.

Conditions

  • Ischemic Stroke
  • Transient Ischemic Attack
  • Type 2 Diabetes Mellitus

Interventions

  • LiraglutideDrug

    The treatment arm will receive the starting dose of liraglutide of 0.6 mg/d subcutaneously once daily, and the dose will be increased to 1.8 mg/d in two weeks, and then continue to administrate this dose for 90 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of patients with the 90-day new stroke events (ischemic or hemorrhagic)Time frame: 90 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Jinan University

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.